Abstract
We experienced a case of a peritoneal dialysis patient with chronic hepatitis C who was successfully treated with PEG-IFN monotherapy. A 50-year old man was undergoing peritoneal dialysis because of diabetic nephropathy. Considering that his HCV genotype was 2, we decided to treat him with PEG-IFN a...
|
PMID: 21873827
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH...
|
PMID: 22057347
PDF is available here.
Merit Cudkowicz,
Michael E Bozik,
Evan W Ingersoll,
Robert Miller,
Hiroshi Mitsumoto,
Jeremy Shefner,
Dan H Moore,
David Schoenfeld,
James L Mather,
Donald Archibald,
Mary Sullivan,
Craig Amburgey,
Juliet Moritz and
Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.